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Abstract
Infections with human respiratory syncytial virus (HRSV) occur glob-
ally in all age groups and can have devastating consequences in
young infants. We demonstrate that a vaccine based on the extracel-
lular domain (SHe) of the small hydrophobic (SH) protein of HRSV,
reduced viral replication in challenged laboratory mice and in cotton
rats. We show that this suppression of viral replication can be trans-
ferred by serum and depends on a functional IgG receptor compart-
ment with a major contribution of FccRI and FccRIII. Using a
conditional cell depletion method, we provide evidence that alveolar
macrophages are involved in the protection by SHe-specific antibod-
ies. HRSV-infected cells abundantly express SH on the cell surface
and are likely the prime target of the humoral immune response elic-
ited by SHe-based vaccination. Finally, natural infection of humans
and experimental infection of mice or cotton rats does not induce a
strong immune response against HRSV SHe. Using SHe as a vaccine
antigen induces immune protection against HRSV by a mechanism
that differs from the natural immune response and from other HRSV
vaccination strategies explored to date. Hence, HRSV vaccine candi-
dates that aim at inducing protective neutralizing antibodies or
T-cell responses could be complemented with a SHe-based antigen
to further improve immune protection.
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Introduction
Human respiratory syncytial virus (HRSV) is the most important
viral cause of acute lower respiratory tract infections (ALRI) in
infants worldwide (Liu et al, 2012). About 66,000–199,000 children
die every year due to complications caused by HRSV infection (Nair
et al, 2010). By the age of 2 years, most children have been infected
at least once by HRSV (Glezen et al, 1986; Hall et al, 1991).
Although in most children HRSV replication remains restricted to
the upper respiratory tract, infection regularly spreads to the lower
respiratory tract, causing bronchiolitis. This inflammation of the
bronchioles is thought to result from massive HRSV infection of the
bronchial and alveolar epithelial cells, resulting in sloughing of
these cells and formation of clumps that occlude the small airways
of the developing infant lungs (DeVincenzo et al, 2005; Welliver
et al, 2008). In high-risk infants, severe HRSV bronchiolitis can be
prevented by prophylactic treatment with palivizumab, a HRSV-
neutralizing monoclonal antibody (IMpact-RSV Study Group, 1998).
Palivizumab, or its affinity-matured variant motavizumab, has
however no therapeutic benefit (Ramilo et al, 2014). A Cochrane
study concluded that therapeutic treatment with aerosolized ribavi-
rin, a guanosine analogue with antiviral activity against both RNA
and DNA viruses, might reduce mortality and days of hospitaliza-
tion in infants with severe HRSV infection (Ventre & Randolph,
2007). Due to its potential teratogenicity, ribavirin is not generally
used to treat HRSV-associated illness. As there is no effective antivi-
ral or anti-inflammatory therapy for HRSV, treatment in hospitals is
mainly supportive and includes fluid and oxygen supply, and
mechanical ventilation. Besides causing acute bronchiolitis, severe
HRSV infections in infants can evoke recurrent wheezing at a later
age and correlate with a predisposition to allergic asthma (Sigurs
et al, 2000; Andreakos, 2012; Blanken et al, 2013).
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The global burden caused by HRSV infections extends beyond
very young children. A study performed by Nair et al (2013)
estimated that annually, HRSV causes about 33.8 million cases
of ALRI and 3.3 million cases of severe ALRI requiring hospital-
ization in children younger than 5 years. In industrialized coun-
tries, deaths due to HRSV ALRI are rare (0.7% of all severe
ALRI) and occur almost exclusively in children younger than
1 year. However, in developing countries, fatal HRSV infections
are more frequent (2.1% of all severe HRSV cases) and remain
frequent at later ages (Nair et al, 2013). Furthermore, HRSV is
increasingly being recognized as a major pathogen in elderly and
immunocompromised adults, and even in previously healthy
adults (Hall et al, 2001; Falsey et al, 2005; Luchsinger et al,
2012).
Despite the medical importance of HRSV and decades of inten-
sive research, there is at present no licensed vaccine for this
virus. A major obstacle and puzzle facing the development of a
vaccine with long-lasting protection is the apparent inability of
natural HRSV infections to elicit protective immunity. This is
illustrated by the recurrence of HRSV infections in all age groups
and the high rate of HRSV infections in infants with maternally
derived HRSV-neutralizing antibodies (Henderson et al, 1979; Hall
et al, 2001; Collins & Graham, 2008). Even healthy individuals
with high levels of neutralizing serum antibodies can be re-
infected, even with the same HRSV strain within, 2–6 months
(Hall et al, 1991).
Vaccines used to prevent or treat infectious diseases aim at
mimicking at least part of the host immune response that accom-
panies recovery from natural infection. In many cases, this implies
the induction of neutralizing antibodies directed against major
surface proteins of the pathogen. Likewise, most HRSV vaccines
being developed aim at inducing HRSV-neutralizing antibodies
directed against either the HRSV attachment protein (G) or the
fusion protein (F) (Graham, 2011). This strategy has not yet
produced an effective HRSV vaccine, but is reasonably still further
explored.
We have explored an alternative, unconventional vaccination
strategy to control HRSV infection. Next to the F and G proteins,
HRSV also expresses a third membrane protein, the small hydro-
phobic (SH) protein (Olmsted & Collins, 1989; Collins et al, 1990).
Although the exact function of SH remains poorly understood, it
folds into pentameric cation-selective ion channels that can acti-
vate the NLRP3 inflammasome (Carter et al, 2010; Gan et al,
2012; Triantafilou et al, 2013). The importance of these functions
remains unknown as recombinant HRSV that lacks SH expression
is not attenuated in vitro and only slightly attenuated in mice and
non-human primates (Bukreyev et al, 1997; Whitehead et al,
1999). Due to its small size and low abundance on HRSV virions,
SH is poorly immunogenic upon natural infections (Connors et al,
1991; Akerlind-Stopner et al, 1993). We generated immunogens
that allowed induction of IgG antibodies directed against the SH
ectodomain (SHe) in laboratory mice and cotton rats. These SHe-
specific antibodies lacked virus-neutralizing activity, readily bound
to the surface of HRSV-infected cells and reduced HRSV replica-
tion in these two animal models. Based on selective immune cell
depletion studies and passive transfer experiments, we also identi-
fied the mechanism of action of this novel HRSV vaccination
approach.
Results
SHe-specific immunity reduces HRSV replication
Experimental or natural infection with HRSV leads to a poor humoral
immune response toward the SH ectodomain (Akerlind-Stopner
et al, 1993; Connors et al, 1991 and see below). Therefore, we first
improved the immunogenicity of a peptide corresponding to SHe
by linking it chemically to keyhole limpet hemocyanin (KLH). The
SHe-KLH conjugate was used to immunize BALB/c mice in combination
with incomplete Freund’s adjuvant (IFA). Using a SHe peptide-based
ELISA, we found that immunization with SHe-KLH induced
SHe-specific serum IgG1 and IgG2a antibodies and that the levels of
IgG antibodies were increased by booster immunizations (Fig 1A–C).
In contrast, little or no SHe-specific IgG antibodies were detected in
mice infected with live HRSV (Fig 8C; Supplementary Fig S2C).
We then investigated whether SHe-specific serum antibodies
from immunized mice could neutralize HRSV infections in an in
vitro plaque reduction assay. In contrast to sera derived from HRSV
A2 infected mice, high-titer SHe immune serum failed to neutralize
this virus in vitro (Fig 1D). To test whether SHe-based immuniza-
tion could counteract HRSV infections, mice were challenged with
1 × 106 plaque-forming units (PFU) of HRSV A2. Compared to
control vaccinated animals, all SHe-KLH-immunized mice displayed
significantly lower pulmonary HRSV titers at 5 days post-infection
(Fig 1E). Furthermore, following challenge, SHe-KLH-immunized
mice had a slightly higher body weight compared to both control
groups (Fig 1F). SHe-specific antibodies were also induced by SHe
peptides conjugated to virus-like particles derived from Hepatitis B
core (HBc) protein and by SHe linked genetically to recombinant
tetrameric and pentameric scaffold proteins, although these
responses were less robust than those induced by SHe-KLH (data
not shown).
To investigate whether the reduction of HRSV replication in SHe-
KLH-vaccinated mice is short living or long living, BALB/c mice
were vaccinated with KLH or SHe-KLH in combination with either
IFA or Sigma Adjuvant System (SAS). As a negative control, mice
were mock-vaccinated with PBS without adjuvant. Immunizations
with IFA were performed three times, whereas immunizations with
SAS were performed twice. Figure 2A and B show that mice immu-
nized with SHe-KLH with either adjuvant had high levels of SHe-
specific serum IgG1 and moderate levels of serum IgG2a at 3 weeks
before viral challenge. Six weeks after the last immunization with
IFA and 8 weeks after the last immunization with SAS adjuvant, the
mice were challenged with 1 × 106 PFU of HRSV A2. At six days
post-challenge, all mice that were vaccinated with SHe-KLH had
significantly lower lung HRSV titers as compared to KLH- or PBS-
vaccinated mice (Fig 2C). Up till 6 days post-infection, no signifi-
cant differences in body weight were observed, although there was
a trend toward somewhat higher relative body weight for SHe-KLH-
immunized mice as compared to KLH-immunized mice (Fig 2D). In
a separate experiment, HRSV challenge was postponed to eleven
weeks after the last immunization with KLH or SHe-KLH in combi-
nation with IFA. Supplementary Fig S1 shows that at eleven weeks
after the last immunization, all mice had high SHe-specific IgG
serum titers that were slightly lower than serum titers at 4 weeks
after the last immunization. Supplementary Fig S1C illustrates that
also when challenge with 1 × 106 PFU, HRSV A2 is performed
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11 weeks after the last immunization, SHe-KLH-vaccinated mice
had significantly lower lung HRSV titers as compared to KLH-vaccinated
mice. Together, these data indicate that the protection afforded by
SHe-based vaccination is relatively long living.
The amino acid sequence of SHe is highly conserved among the
group A HRSV but differs substantially from SHe in group B HRSV
where it is also sequence conserved (Supplementary Figs S10 and S11)
(Collins et al, 1990). Consequently, it is likely that vaccination against
HRSV B subgroup viruses would require a subgroup-B-matched SHe
(SHe-B). Immunization of mice with an SHe-B peptide conjugated to
HBc-VLP-induced SHe-B-specific serum IgG that reacted poorly with
SHe of subgroup A HRSV (Supplementary Fig S2A–C). These sera
however readily bound to the surface of cells infected with HRSV B
(Supplementary Fig S2D). To test whether SHe-B immunization affects
HRSV B replication in mice, we investigated whether replicating virus
could be isolated from the lungs of BALB/c mice infected with a labo-
ratory strain of HRSV B (HRSV B1) or with HRSV B clinical isolates
(JX576729, JX576730, JX576731 in Supplementary Fig S11) (Tan et al,
2013a,b). Despite several attempts, we could not isolate replicating
virus from the lungs of mice that had been infected with any of these
HRSV B strains. However, infection of BALB/c mice with clinical HRSV
B isolates caused significant body weight loss and pulmonary infiltra-
tion of leukocytes (data not shown). Therefore, as a read out for
protection against HRSV B, we monitored body weight loss and cellu-
lar infiltration of the lungs of mice infected with clinical HRSV B isolate
JX576731. BALB/c mice were vaccinated three times with HBc-SHeB,
with unconjugated HBc, both in combination with IFA, or were mock
vaccinated with PBS (Supplementary Fig S2). Due to the high degree of
conservation of the F protein between HRSV A and HRSV B subgroup
viruses, HRSV A infections induce HRSV B neutralizing antibodies
(White et al, 2005). Therefore, prior infection with HRSV A2 was
included as a positive control. Three weeks after the last immuniza-
tion, the mice were challenged with 1.5 × 106 PFU of HRSV B. Seven
days after infection, there was a trend toward lower body weight loss,
less pulmonary CD8+T-cell infiltration, and lower levels of HRSV
B-specific RNA in the lungs of HBc-SHeB-vaccinated mice as compared
to HBc-vaccinated control mice (Supplementary Fig S2E–G). Prior
infection with HRSV A strongly reduced the levels of HRSV B-specific
RNA in the lungs but failed to prevent body weight loss and pulmonary
cell infiltration. These data suggest that SHe-B based vaccination might
also hamper HRSV B replication in vivo. To test the potential cross-
reactivity between SHe of HRSV A and HRSV B viruses, KLH, SHe-
KLH, and HBc-SHeB immune sera were tested in a SHeA and SHeB
peptide ELISA. Supplementary Fig S2I–J show that SHeA peptide is
bound by SHeA-KLH immune serum and not by HBc-SHeB immune
serum. Accordingly, SHeB peptide can only be bound by HBc-SHeB
A B C
D E F
Figure 1. Immunization with SHe conjugate vaccine reduces HRSV replication in BALB/c mice.
SHe-KLH immunization induces SHe-specific serum IgG antibodies. BALB/c mice were immunized 3 times intraperitoneally with 20 lg KLH or SHe-KLH combined with
incomplete Freund’s adjuvant or with PBS. Serum was collected one day before the first immunization and 20 days after each immunization.
A Endpoint IgG titers of pooled sera from each group (n = 6, except PBS group: n = 3) tested in a SHe peptide ELISA.
B Individual SHe-specific serum IgG titers obtained 20 days after the second boost immunization. Horizontal bars represent the median.
C SHe-specific serum IgG, IgG1, and IgG2 endpoint titers in pooled sera after the second boost immunization.
D SHe-KLH immune serum does not neutralize HRSV in vitro. An HRSV A2 in vitro neutralization assay using the indicated dilutions of pooled sera, obtained after the
second boost vaccination of BALB/c mice immunized as in (A), was performed. RSV: serum from BALB/c mice that were previously infected with HRSV A2. The amount
of viral antigen was quantified by ELISA using goat anti-HRSV immune serum. The graph shows the O.D. for each sample.
E Vaccination with SHe-KLH reduces HRSV A2 replication in the lungs of challenged BALB/c mice. The graph shows the number of PFU per lung for each mouse,
sampled 5 days after challenge with 106 PFU of HRSV A2. Horizontal bars depict the median value (Dunn’s multiple comparisons test).
F Challenged SHe-KLH-immunized BALB/c mice do not display weight loss. The graphs are representative for two independent experiments, and horizontal bars depict
the mean value.
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immune serum and not by SHeA-KLH immune serum. Hence to cover
both HRSV A and HRSV B viruses, a SHe-based vaccine should contain
both the SHeA and SHeB antigen.
SHe-based vaccination reduces HRSV replication in cotton rats
Cotton rats are more permissive for HRSV infection than laboratory
mice (Byrd & Prince, 1997). Therefore, we also evaluated SHe-based
immune protection in this animal model. Cotton rats (six animals
per group) were immunized three times intraperitoneally with KLH
or SHe-KLH in combination with IFA, or with PBS. Two booster
immunizations were given after 3-week intervals. As positive
control for protection, one group of cotton rats was infected with
HRSV A Tracy (GA1 genotype) at the time of priming of vaccinated
animals. Enhancement of disease, characterized by increased alveo-
litis and alveolar eosinophilia, upon infection with HRSV of forma-
lin-inactivated HRSV (FI-HRSV) vaccine recipients can be
recapitulated in cotton rats (Piedra et al, 1989; Boukhvalova et al,
2009). Because our SHe-based vaccine approach does not mimic
natural immunity and does not induce an in vitro neutralizing
response, we wanted to ascertain that this approach was safe. As a
positive control for exacerbation of disease following HRSV A infec-
tion, one group of cotton rats was immunized with alum-adjuvanted
formalin-inactivated HRSV A Bernett (GA1 genotype). In agreement
with our findings in laboratory mice, SHe-KLH elicited high levels of
SHe-specific serum IgG antibodies in cotton rats. Also in cotton rats,
HRSV A infection did not elicit detectable SHe-specific serum IgG,
nor could SHe-specific IgG be detected in sera from cotton rats that
had been immunized with FI-HRSV (Fig 3A and B). HRSV infection
or immunization with FI-HRSV plus alum-induced protective levels
of HRSV A neutralizing serum antibodies (Fig 3C). In contrast,
HRSV A neutralizing activity was undetectable in sera from cotton
rats immunized with SHe-KLH (Fig 3C). Despite the absence of
HRSV A neutralizing antibodies, challenged SHe-immunized cotton
rats displayed a tenfold lower pulmonary HRSV A titer as compared
to KLH-immunized cotton rats, a difference that was statistically
A B
C D
Figure 2. The reduction of HRSV in SHe-KLH-immunized mice is not short living.
Two groups of 8 BALB/c mice were immunized three times intraperitoneally with KLH or SHe-KLH combined with incomplete Freund’s adjuvant (KLH IFA and SHe-KLH IFA). In
parallel, two groups of 7mice were immunized two times intraperitoneally with KLH or SHe-KLH in combinationwith Sigma Adjuvant System (KLH SAS and SHe-KLH SAS). As a
third immunization, the latter two groups received PBS without adjuvant. As negative control, one group of 8 mice was vaccinated with PBS without adjuvant (PBS). All
immunizations were performed every 2 weeks. Serum was collected 20 days after each immunization. Six weeks after the last immunization with incomplete Freund’s
adjuvant and 8 weeks after the last immunization with Sigma Adjuvant System, the mice were challenged with 1 × 106 PFU HRSV A2. Six days after challenge, the lungs were
collected to determine the pulmonary HRSV titer by plaque assay.
A SHe-KLH immunization induces SHe-specific serum IgG1 antibodies. The graph shows the SHe-specific IgG1 serum endpoint titers of each mouse at 3 weeks before
viral challenge as determined by SHe peptide ELISA. Horizontal bars indicate the mean IgG1 titers.
B SHe-KLH immunization induces SHe-specific serum IgG2a antibodies. The graph shows the SHe-specific IgG2a serum endpoint titers of each mouse at 3 weeks before
viral challenge as determined by SHe peptide ELISA. Horizontal bars indicate the mean IgG2a titers.
C Vaccination with SHe-KLH reduces HRSV A2 replication in the lungs of challenged BALB/c mice. The graph shows the number of PFU per lung for each mouse,
sampled 6 days after challenge with 1 × 106 PFU of HRSV A2. Horizontal bars represent the median (one-way ANOVA Dunn’s multiple comparisons test).
D Vaccination with SHe-KLH is not associated with enhanced body weight loss upon HRSV infection. The graph shows the relative body weight at day 6 post-infection
calculated as the ratio between body weight at day 6 and body weight at day 0. Horizontal bars represent the median.
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Figure 3. SHe-KLH immunization reduces pulmonary HRSV replication in cotton rats.
Cotton rats (n = 6 per group) were immunized three times intraperitoneally with 20 lg of KLH or SHe-KLH combined with incomplete Freund’s adjuvant or with PBS.
Additional groups of animals were infected once intranasally with live HRSV or immunized once intramuscularly with formalin-inactivated HRSV (FI-HRSV) at the same time
of priming of the other groups. Serum was collected one day before the first immunization and 20 days after each immunization (boost one and two).
A Endpoint titer of SHe-specific IgG in pooled sera after each immunization.
B Individual SHe-specific serum IgG endpoint titers, sampled 20 days after the second boost. Horizontal bars represent the mean.
C SHe-KLH immune cotton rat serum does not neutralize HRSV in vitro. The graph shows the HRSV-neutralizing titer in serum isolated 20 days after boost
immunization of each cotton rat. Note: One animal that was vaccinated with FI-RSV died before HRSV challenge. Horizontal bars represent the mean.
D Vaccination with SHe-KLH reduces HRSV replication in the lungs of challenged cotton rats. The graph shows the number of PFU/g of lung tissue for each animal,
sampled 5 days post-infection with 2.25 × 105 PFU of HRSV Tracy. Horizontal bars represent the mean (unpaired 2-sided Mann–Whitney U-test). Note: One animal in
the KLH and one animal in the PBS-vaccinated group died after HRSV challenge.
E HRSV titers in the upper respiratory tract of challenged cotton rats. The graph shows the number of PFU per nasal wash for each animal, sampled 5 days post-
infection with 2.25 × 105 PFU of HRSV Tracy. Horizontal bars represent the mean (unpaired 2-sided Mann–Whitney U-test).
F Alveolitis area score for the lungs of each animal (one-way ANOVA Dunn’s multiple comparisons test).
G Alveolitis severity score for the lungs of each anima (one-way ANOVA Dunn’s multiple comparisons test).
H Representative Micrographs (20×) of H&E-stained lung sections. Scale bars: 100 lm.
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significant (Fig 3D). SHe-KLH-immunized cotton rats also displayed
a trend toward reduced HRSV A titers in the nasal tract compared to
KLH control animals (Fig 3E). Importantly, and in contrast to chal-
lenged FI-HRSV immunized cotton rats, HRSV A challenge of SHe-
KLH-immunized animals was not associated with alveolitis or
pulmonary infiltration of eosinophils upon HRSV A infection, indi-
cating that vaccination with SHe-KLH in combination with IFA does
not exacerbate pulmonary pathology upon infection in cotton rats
(Fig 3F–H; Supplementary Fig S3A–J).
Adoptive transfer of SHe-specific immune serum reduces HRSV
replication and associated morbidity in mice
Because SHe-based immunization is associated with reduced HRSV
replication upon challenge of mice and cotton rats in the absence of
demonstrable neutralizing antibodies, we first investigated whether
SHe-specific antibodies contributed to protection. We administered
serum from mice immunized with PBS, KLH, or SHe-KLH intranasally
into naive mice 1 day before and 1 day after HRSV challenge with
5 × 105 PFU of HRSV A2. Five days after infection, the pulmonary
HRSV titer was determined. Figure 4A shows that lung virus titers
were significantly lower in mice that had been treated with SHe-KLH
immune serum compared to mice that had received PBS or KLH
immune serum. To investigate the dose effect of passive immuniza-
tion with SHe immune serum, different amounts ranging from 0 to
50 ll of SHe-KLH serum were administered intranasally to mice 1 day
before and 1 day after HRSV challenge. All administrated sera were
adjusted to a final volume of 50 ll using KLH immune serum.
Whereas a dose of 5 ll SHe immune serum could reduce the lung
HRSV titer by threefold, 25 and 50 ll SHe immune serum reduced the
lung HRSV titer by 11 and 17-fold, respectively, on day 5 after
infection (Supplementary Fig S4A and B). None of the mice displayed
body weight loss during the experiment (Supplementary Fig S4C and
D). To test whether next to intranasal administration also parenteral
passive immunization with SHe immune serum could reduce HRSV
replication, KLH or SHe-KLH immune serum or HRSV convalescent
serum was injected intraperitoneally 16 h before HRSV challenge.
Supplementary Fig S4C and D illustrates that also parenteral adminis-
tration of SHe-KLH immune serum can hamper HRSV replication
although to a lesser extent than HRSV convalescent serum.
Although HRSV replicates poorly in mice, challenge of BALB/c
mice with a high viral dose is often associated with considerable
body weight loss (Graham, 2011). To test whether SHe-specific
antibodies can reduce this type of HRSV-induced morbidity, mice
were treated with SHe-KLH or control KLH immune serum or with
convalescent serum from mice that had been challenged with
HRSV. Mice that were not treated and not infected (NI) were used
as negative control for HRSV-associated body weight loss. Next,
we challenged the animals with a dose of 107 PFU of HRSV A2
and monitored body weight. From day five after infection
onwards, all challenged mice started to lose weight (Fig 4B).
However, from day 6 after challenge, mice that had received SHe
or HRSV immune serum started to recover, whereas mice that had
been treated with KLH immune serum continued to lose weight
and recovered significantly more slowly (Fig 4B). We conclude
that SHe-KLH immune serum reduces HRSV replication and associ-
ated body weight loss in mice.
SHe-antibody-based immune protection depends on
Fcc receptors
SHe-specific antibodies failed to neutralize HRSV in vitro, yet SHe-
specific immune serum reduced HRSV replication in vivo, indicating
that an alternative mechanism of protection was operating in vivo.
Antibodies that are directed against virus surface antigens can coop-
erate with leukocytes to kill or remove virus-infected cells by mech-
anisms that require Fc receptors on the surface of different types of
leukocytes, including NK cells, macrophages, dendritic cells,
neutrophils, and eosinophils (Bruhns, 2012; Jiang et al, 2011). To
test whether Fcc receptors are involved in the control of HRSV
A B
Figure 4. SHe immune serum reduces pulmonary HRSV replication and morbidity.
A One day before and one day after HRSV A2 infection, BALB/c mice were treated intranasally with 35 ll of PBS (PBS), KLH (KLH) or SHe-KLH immune serum (SHe-KLH).
Five days after challenge with 5 × 105 PFU of HRSV A2, the lungs were collected to determine HRSV A2 titers. The graph shows the number of HRSV plaques per lung
for each mouse 5 days after infection. Horizontal bars represent the mean (one-way ANOVA Dunn’s multiple comparisons test).
B Passively transferred SHe-KLH immune serum reduces body weight loss in HRSV-challenged mice. One day before and one day after infection with 1 × 107 PFU of
HRSV A2, BALB/c mice were treated intranasally with 35 ll, KLH, or SHe-KLH immune serum. In addition, one group of mice received serum from mice that had been
infected with HRSV. Mice that were not treated and not infected (NI) were used as additional control. The graph represents the average relative (compared to day 0)
body weight  SEM of all mice in each group (n = 6, two-way ANOVA Tukey’s multiple comparisons test, the indicated P-value’s concern differences between the
KLH and SHe-KLH groups).
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replication mediated by SHe immune serum, we performed adoptive
serum transfer experiments in BALB/c mice with a targeted disrup-
tion of the activating receptors FccRI and FccRIII (Fig 5A) (Hazenbos
et al, 1996; Meyer et al, 1998; Nimmerjahn & Ravetch, 2006). HRSV
challenge of wild-type and (FccRI, FccRIII)/ BALB/c mice that
had received KLH control immune serum had comparable levels of
HRSV in their lungs, indicating that these two mouse strains are
equally susceptible to HRSV (Fig 5B) (Bukreyev et al, 2008). As
expected, SHe immune serum significantly reduced HRSV titers in
the lungs of wild-type BALB/c mice. In contrast, adoptively trans-
ferred SHe immune serum failed to reduce pulmonary HRSV titers
in (FccRI, FccRIII)/ mice. As Fcc receptors are involved in the
pharmacokinetics of IgG, we investigated whether the failure of SHe
immune serum to reduce HRSV replication in (FccRI, FccRIII)/
mice might be due to lower levels of SHe-specific IgG antibodies
in the lungs (Wang et al, 2008). SHe peptide ELISA of lung homo-
genates revealed that the levels of SHe-specific IgG were comparable
in wild-type and (FccRI, FccRIII)/ mice (Fig 5C). We conclude
that SH-specific IgG require FccRI and or FccRIII to reduce pulmo-
nary HRSV replication in mouse.
SHe-antibody-based immune protection depends on
alveolar macrophages
There are three activating Fcc receptors in mouse: FccRI, FccRIII,
and FccRIV (Nimmerjahn & Ravetch, 2006). These as well as the
inhibitory receptor FccRII are differentially expressed on myeloid
and lymphoid cells (Bruhns, 2012). NK cells, for example, can kill
infected cells through FccRIII-mediated antibody-dependent cell-
mediated cytotoxicity. As NK cells infiltrate the lungs early during
HRSV infection (Hussell & Openshaw, 1998; Moore et al, 2008), we
tested whether NK cells are involved in SHe-specific IgG-mediated
immune protection. To deplete NK cells and prevent NK cell infiltra-
tion in the lungs, we treated BALB/c mice with anti-asialoGM1 or
rabbit control serum (Supplementary Fig S5A). Treatment of HRSV-
infected mice with anti-asialoGM1 antibodies reduced NK cell
infiltration in the lungs at 3 days post-infection (Supplementary Fig
S5B–D). Anti-asialoGM1 antibody treatment did however not signifi-
cantly impact the of pulmonary HRSV replication in mice passively
immunized with SHe immune serum (Supplementary Fig S5E).
These data indicate that NK cells do not play a pivotal role in SHe-
specific IgG-mediated control of HRSV replication.
Alveolar macrophages are the most abundant cell type in the
lumen of normal, non-infected lungs. Recently, the presence of
FccRI on the surface of mouse alveolar macrophages has been illus-
trated by the enhanced binding of FccRI-specific antibodies as
compared to isotype control antibodies (Bruhns, 2012; Guilliams
et al, 2014). To confirm the expression of FccRI on the surface of
mouse alveolar macrophages, we tested the binding of FccRI-
specific antibodies on the surface of alveolar macrophages isolated
from the BALF of wild-type and FccRI/ mice by flow cytometry.
BALF cells of wild-type mice and FccRI/ mice were stained with
either IgG1j anti-mouse FccRI-specific antibody or an IgG1j isotype
control antibody both in combination with anti-CD11c antibody.
Resident alveolar macrophages were detected as autofluorescent
(FITC channel), CD11c-positive cells. Supplementary Fig S6 illus-
trates that in contrast to FccRI/ alveolar macrophages, alveolar
macrophages from wild-type mice are readily recognized by anti-
FccRI antibodies. These data confirm that alveolar macrophages
do indeed express FccRI. Next, we examined the role of resident
alveolar macrophages in SHe-antibody-mediated control of HRSV
replication by depleting these cells with clodronate-loaded lipo-
somes (Fig 6A) (Van Rooijen & Sanders, 1994; Pribul et al, 2008; El
Bakkouri et al, 2011). Prior intranasal administration of clodronate-
loaded liposomes reduced the number of alveolar macrophages by
approximately 70% on the day of infection (Fig 6B). As expected, in
HRSV-challenged mice that were treated with PBS, intranasal
administration of SHe immune serum significantly reduced the
A B C
Figure 5. Reduction of HRSV replication by SHe immune serum depends on Fcc receptors I and/or III.
A Schematic overview of the protocol used to investigate the role of Fcc receptors in SHe-antibody-mediated reduction of HRSV replication. One day before and one
day after HRSV A2 infection, wild-type (WT, 6 mice per group) or Fcc receptor I and III double knockout (FccR I/III/, 5 mice per group) BALB/c mice were treated
intranasally with 35 ll of PBS (PBS), KLH (KLH) or SHe-KLH immune serum (SHe-KLH). Five days after challenge with 5 × 105 PFU of HRSV A2, the lungs were collected
and HRSV A2 titers were determined by plaque assay.
B Transfer of SHe-KLH immune serum reduces HRSV replication in wild-type, but not in FccR I/III/ mice. The graph shows the number of PFU per lung of each mouse,
and horizontal bars represent the means (one-way ANOVA Dunn’s multiple comparisons test).
C SHe-specific IgG levels in lung homogenates of wild-type and FccR I/III/ mice are comparable. The graph shows the SHe-specific endpoint IgG titer in lung
homogenates prepared 5 days after infection of each mouse treated with SHe-KLH immune serum, with horizontal bars representing the mean. The graphs are
representative for two independent experiments.
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pulmonary HRSV titer as compared to KLH immune serum and was
associated with a slightly higher body weight after challenge (Fig 6C
and D). In mice that had received control KLH immune serum,
depletion of monocytes by clodronate-loaded liposomes did not
significantly affect the HRSV pulmonary titer (Fig 6C). In contrast,
treatment with clodronate-loaded liposomes partially but signifi-
cantly restored HRSV replication in the lungs of mice that had been
treated with SHe immune serum (Fig 6C). Importantly, pulmonary
SHe-specific IgG antibodies were not lower but rather higher in the
mice with depleted alveolar macrophages (Fig 6E). This is in line
with the role of macrophages in the clearance of IgG (Ordas et al,
2012; Wang et al, 2008). To investigate the contribution of alveolar
macrophages at different time points during HRSV infection, the
pervious experiment was repeated but instead of at 5 days post-
infection, the lungs were collected at 4 and 6 days post-infection. As
expected in mice that were not treated with clodronate-loaded lipo-
somes, intranasal administration of SHe-KLH immune serum signifi-




Figure 6. Suppression of HRSV replication by SHe immune serum depends on alveolar macrophages.
A Schematic overview of the protocol used to investigate the role of alveolar macrophages in SHe-antibody-mediated protection against HRSV. Three days before
infection, anesthetized BALB/c mice were treated intranasally with PBS (PBS) or clodronate-loaded liposomes (Cl. Lip.). One day before and one day after HRSV A2
infection, the mice received KLH (KLH) or SHe-KLH immune serum (SHe-KLH) via the intranasal route. On day 5 after challenge with 5 × 105 PFU of HRSV A2, mice
were sacrificed and the pulmonary viral load was determined by plaque assay.
B Treatment with clodronate-loaded liposomes selectively reduces the number of alveolar macrophages in the lungs. Mice were treated with PBS or clodronate-
loaded liposomes 3 days before BAL fluid collection. Two days later, these mice were additionally treated with PBS or KLH immune serum. The number and type of
cells in the BAL fluid was determined by flow cytometry. The graph represents the number of CD8+ T cells (CD8+), CD4+ T cells (CD4+), neutrophils (neut.),
eosinophils (eos.), resident alveolar macrophages (rAM), infiltrating monocytes (Mon.), and dendritic cells (DC) in BAL fluid. PBS/PBS: passive transfer of PBS and
treatment with PBS; PBS/Cl. lip.: passive transfer of PBS and treatment with clodronate-loaded liposomes; serum/PBS: passive transfer of KLH immune serum and
treatment with PBS; Serum/Cl. lip.: passive transfer of KLH immune serum and treatment with clodronate-loaded liposomes.
C Treatment of mice with clodronate-loaded liposomes impairs SHe-immune serum-mediated suppression of HRSV replication. The graph shows the number of PFU
per lung of each mouse on day 5 after challenge. Horizontal bars represent the means (one-way ANOVA Dunn’s multiple comparisons test). The graph is
representative for two independent experiments.
D Depletion of alveolar macrophages does not affect body weight upon HRSV infection. The graph shows the relative body weight of each animal on day 5 after
infection and horizontal bars depict the mean.
E Depletion of alveolar macrophages does not decrease the amount of SHe-specific IgG in the lung. The graph shows the SHe-specific IgG endpoint titers in cleared
lung homogenates prepared on day 5 after challenge with HRSV A2, as determined by a SHe peptide ELISA. Horizontal bars represent the mean.
F, G BALB/c mice (n = 16 per group) were immunized three times with KLH or SHe-KLH in combination with incomplete Freund’s adjuvant. Immunizations were
performed intraperitoneally with 3-week interval. Nineteen days after the last immunization, half of the mice were treated with, respectively, PBS (KLH PBS and
SHe-KLH PBS) or clodronate-loaded liposomes (KLH Cl. Lip. and SHe-KLH Cl. Lip.). Three days later, all mice were challenged with 1 × 106 PFU RSV A2. Five days
after challenge, the lungs were collected for HRSV titration. (F) SHe-specific IgG endpoint titers of sera collected 2 weeks after the last immunization, as tested by
SHe peptide ELISA. Horizontal bars represent the mean. (G) The reduction of HRSV replication in SHe-KLH-vaccinated mice depends on alveolar macrophages. The
graph shows the number of PFU per lung for each mouse. Horizontal bars represent the means (one-way ANOVA Tukey’s multiple comparisons test).
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approximately tenfold (Supplementary Fig S7A). In contrast, in
mice in which the resident alveolar macrophages were depleted by
clodronate-loaded liposomes, there was only a twofold, statistically
not significant, reduction in lung HRSV titer in mice that were
treated with SHe-KLH immune serum as compared to mice that
were treated with KLH immune serum (Supplementary Fig S7A). At
6 days after infection, the reduction (approximately 110-fold) of
HRSV replication in the lungs of SHe-KLH immune serum treated
mice was more pronounced than at 4 days post-infection (Supple-
mentary Fig S7C). In mice in which the resident alveolar macro-
phages were depleted by clodronate-loaded liposomes, treatment
with SHe-KLH immune serum still reduced the lung viral titer by
approximately 15-fold. Supplementary Fig S7B and D illustrate that
the reduced effect of SHe immune serum in mice with depleted alve-
olar macrophages is not due to lower SHe-specific IgG titers in the
lungs of these mice. These data indicate that at later time points
during HRSV infections, other, possibly infiltrating, leukocytes aid
at reducing HRSV replication in the lungs.
Because the intranasal route of serum administration might affect
the mechanism by which SHe-specific antibodies hamper HRSV
replication in the lungs, the role of alveolar macrophages was also
investigated when SHe immune serum was administered parentally.
Supplementary Fig S8A and B illustrate that depletion of alveolar
macrophages abrogated the reduction of HRSV replication in mice
that were treated with SHe immune serum by intraperitoneal injec-
tion. To further investigate the role of alveolar macrophages, we
tested whether depletion of alveolar macrophages also impairs
protection afforded by active SHe vaccination. Mice were vaccinated
with KLH or SHe-KLH in combination with IFA. Nineteen days after
the last immunization, half of the mice were treated with PBS or
clodronate-loaded liposomes. Three days later, all mice were chal-
lenged with 1 × 106 PFU RSV A2. Five days after challenge, the
lungs were collected for HRSV titration. Figure 6F shows that at
3 weeks after the last immunization, mice that were treated with
clodronate-loaded liposomes had comparable levels of SHe-specific
serum IgG as mock-treated mice. However, in contrast to mock-
treated mice, mice that were treated with clodronate liposomes,
SHe-KLH vaccination did not reduce HRSV replication in the lungs
(Fig 6G). Taken together, these data indicate that SHe-specific anti-
bodies reduce HRSV replication by a mechanism involving Fcc
receptors and alveolar macrophages. However, especially at later
time points after infection, also other leukocytes might be involved.
SHe-specific antibodies bind to HRSV-infected cells but barely to
HRSV virions
Virus-specific antibodies can affect virus replication by multiple
ways ranging from direct virus neutralization to engaging Fc
receptor-expressing cells that remove IgG-opsonized virus particles
or remove and kill infected cells. To discriminate between an Fcc
receptor mechanism targeting HRSV virions or infected cells, we
tested to what extent SHe-specific IgG antibodies in SHe immune
serum can bind HRSV virions or HRSV-infected cells. This was
investigated by an immunostaining experiment in which the binding
of SHe-specific IgG antibodies present in SHe-KLH immune serum to
the surface of HRSV A2-infected A549 cells was compared to bind-
ing to HRSV A2 virions attached to the surface of A549 cells at 4°C.
Because the F protein is readily accessible at the surface of infected
cells and virions, a HRSV F-specific IgG monoclonal antibody was
used as positive control (Magro et al, 2010). Polyclonal anti-HRSV
goat immune serum was used to identify the HRSV-infected cells
and HRSV virions. Polyclonal anti-HRSV serum recognized the
surface of the infected cells, including the long filaments and espe-
cially the sprouts of these filaments (Fig 7A and B). Reactivity of the
F protein-specific monoclonal antibody was largely confined to the
cell surface and filament tips. Since these F-rich tips are of similar
size and have an F protein staining pattern that is similar to HRSV
virions that are attached to the target cells (Fig 7C), it is likely
that these sprouts correspond to budding virions. Similar to the
F-specific monoclonal antibody and polyclonal anti-HRSV immune
serum, SHe immune serum readily recognized the surface of HRSV-
infected cells. However, in contrast to the F-specific monoclonal
antibody, SHe immune serum barely bound to the filament tips
(Fig 7A and D). In a second approach, performed in parallel, we
studied the binding of SHe-specific antibodies to HRSV virions that
were attached to but not yet fused with A549 cells (Schepens et al,
2011). HRSV virions were recognized by both polyclonal anti-HRSV
serum and the F protein-specific monoclonal antibody (Fig 7C and
D). More specifically, all virions that were stained by the polyclonal
HRSV serum were also recognized by the monoclonal anti-F protein
antibody. In contrast, SHe immune serum largely failed to bind to
HRSV virions (Fig 7A, C and D). Taken together, these results
suggest that SHe immune serum reduces HRSV replication in vivo
by a mechanism that targets HRSV-infected cells rather than virions.
Human sera lack high levels of SHe-specific antibodies
Many of the current HRSV vaccine approaches aim at inducing
HRSV-neutralizing antibodies directed against the F or G protein.
However, most adults already have high levels of HRSV-neutralizing
serum antibodies. To investigate the levels of SHe-specific IgG in
sera of adults, we used SHe peptide ELISA to examine a panel of
reference sera with varying levels of HRSV-neutralizing antibodies,
as well as purified human serum IgG (Yang et al, 2007). In contrast
to serum from SHe-KLH-vaccinated mice, sera from HRSV-infected
or KLH-vaccinated mice and all human sera lacked detectable SHe-
specific IgG antibodies (Fig 8A and C). Still, all tested human sera
and sera from HRSV-infected or SHe-KLH-immunized mice readily
recognized HRSV proteins in lysates of HRSV-infected cells (Fig 8B
and D). These data suggest that HRSV infections in humans do not
induce long-living high levels of SHe-specific IgG.
Discussion
Although the identification of HRSV as an important cause of bron-
chiolitis in infants was made more than 55 years ago, there is still
no licensed vaccine for this important respiratory pathogen (Collins
& Graham, 2008). Most attempts to develop such a vaccine aim at
inducing neutralizing antibodies directed against the major surface
proteins, F and G (Graham, 2011). Inducing neutralizing serum anti-
bodies is a reasonable approach because different reports have illus-
trated that high levels of such antibodies correlate with reduced
disease (Piedra et al, 2003; Luchsinger et al, 2012; Glezen et al,
1986). Moreover, prophylactic passive immunization of high-risk
infants with the humanized monoclonal antibody palivizumab,
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which is F specific and virus neutralizing, reduces the risk of HRSV-
associated hospitalization by approximately 50% (IMpact-RSV
Study Group, 1998). However, natural HRSV infection does not
induce long-lasting immunity. Unlike human influenza, this lack of
protection against reinfection occurs without significant antigenic
drift (Collins & Graham, 2008). Apart from a recently described
neutralizing epitope that is unique to the prefusion conformation of
F, the fusion protein of HRSV is highly conserved (McLellan et al,
2013). Healthy adults with high levels of neutralizing antibodies in
circulation can be experimentally reinfected with HRSV (Hall et al,
1991). In addition, some studies even reported a lack of demonstra-
ble correlation between high levels of serum neutralizing antibodies
and protection against severe disease caused by HRSV (Friedewald
et al, 1968; Mills et al, 1971; Falsey & Walsh, 1992; Brandenburg
et al, 1997; Falsey et al, 1999; Wright et al, 2002). Taken together,
it remains to be determined whether vaccination strategies that
mimic the host immune response following natural infection with
HRSV could provide significant protection.
We developed an alternative vaccination strategy that is not
based on natural correlates of protection. In contrast to the major
A C
B D
Figure 7. SHe-specific IgG binds to HRSV-infected cells.
A–C A549 cells were infected overnight with 0.5 MOI HRSV A2 (A), mock-infected (B). In parallel, A549 cells were incubated with 5 MOI HRSV A2 at 4°C for 2 h to allow
virus attachment without cell entry (C). After infection or virus attachment, the cells were fixed and stained with SHe-KLH mouse immune serum, KLH mouse
immune serum, or a HRSV F-specific mouse monoclonal antibody. Reactivity of mouse IgG was revealed with a green fluorescently labeled secondary antibody. In
addition, cells were stained with a polyclonal goat anti-HRSV immune serum, followed by a red fluorescently labeled secondary anti-goat antibody. Nuclei were
stained with DAPI (blue color). Confocal images were recorded with a Zeiss SP5 confocal microscope. The upper row of each figure shows the overlay of the red
(anti-HRSV), green (indicated serum or antibodies) and the blue (DAPI) signal. The scale bars in the right lower corner of the overlay images indicate 20 lm.
D Quantification of virion-associated immunoreactivity of F, SHe-KLH, and KLH mouse IgG on cell-attached HRSV A2 virus particles. This quantification is based on
image analysis of multiple micrographs obtained with the attachment and immunostaining experiment shown in (B). The graph shows for each cell-attached
virion the ratio of a/b, with ‘a’ being the total pixel intensities of either bound HRSV F-specific monoclonal IgG antibodies (F mAb), SHe-KLH or KLH immune serum
IgG and with ‘b’ being the total pixel intensities of bound goat anti-HRSV IgG antibodies. The virions were identified as anti-RSV IgG-positive regions. Multiples
images were used for this analysis. Horizontal bars represent the median.
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surface proteins, F and G, the SH protein does not elicit high levels
of antibodies or contribute to protection upon infection (Connors
et al, 1991; Akerlind-Stopner et al, 1993). SH is a pentameric
membrane protein that is not absolutely required for in vitro virus
growth but presumably modulates the host innate immune response
and it is essential for in vivo viral fitness (Bukreyev et al, 1997; Gan
et al, 2012; Triantafilou et al, 2013).
The inability of HRSV infections to induce high levels of SHe-
specific antibodies can be explained by the close proximity of this
24 amino acid long ectodomain to the cell and viral membrane and
because of its limited incorporation into budding virions (Rixon
et al, 2004). We confirmed the findings of Rixon et al, which were
obtained by immune electron microscopy, by immunostaining
HRSV virions attached to the surface of target cells.
In agreement with the weak immunogenicity of the SH ectodo-
main upon HRSV infection and the weak or absent binding of SHe
IgG to HRSV virions, SHe immune sera failed to neutralize HRSV in
vitro. Passive immunization of mice with heat-inactivated SHe
immune serum revealed that SHe-specific antibodies were associ-
ated with reduced pulmonary HRSV replication, suggesting that
these antibodies are prime mediators of immune protection by this
novel SHe-based HRSV vaccination approach. Next to SHe-specific
antibodies, SHe-specific T cells might also be involved in SHe-
vaccination-mediated reduction of viral replication. In mouse, a
CD4+ T-cell epitope within SHe, and in humans, a CD8+ T cells
epitope within the SH protein have been reported (Nicholas et al,
1989; Cherrie et al, 1992). However, we could not detect SHe-
specific T cells in the spleens of HRSV-infected mice by ELISPOT or
by intracellular cytokine staining, whereas F-specific CD8+ T cells
were readily detected in the spleens of these HRSV-infected mice
(unpublished data). Moreover, depletion of CD8 cells upon HRSV
challenge did not abolish the reduction of HRSV in SHe vaccinated
mice Supplementary Fig S9).
Apart from direct neutralization of viral particles, antibodies can
also combat viral infections by opsonizing viral particles, marking
them for uptake by phagocytes or complement-dependent lysis, or
by initiating the elimination of infected cells through antibody-
dependent cellular cytotoxicity (ADCC), antibody-dependent cellular
phagocytosis (ADCP), or complement-dependent cytotoxicity (CDC)
(Hogarth & Pietersz, 2012). ADCC and ADCP depend on activating
Fc receptors FccRI, FccRIII, or FccRIV in mouse and on FccRI,
FccRIIA, FccRIIC, and FccRIIIB in human (Nimmerjahn & Ravetch,
2006; Bruhns, 2012). These receptors are expressed alone or
combined with other activating and/or silencing Fcc receptors
A B
C D
Figure 8. Human sera with high HRSV-neutralizing activity lack high levels of SHe-specific IgG.
A–D SHe peptide ELISA of human (A) and mouse (C) sera. Human reference sera to HRSV were obtained from the NIH Biodefense and Emerging Infections Research
Resources Repository (NIAID, NIH). Antiserum NR-4020: pooled human reference serum; NR-4021: pooled human sera with high HRSV neutralization titer;
NR-4022: pooled human sera with intermediate HRSV neutralization titer: NR-4023: pooled human sera with low HRSV neutralization titer; and NR-21973: human
reference Ig to HRSV (1% Ig in PBS). The mouse sera represent pooled pre-immune sera (pre.), pooled immune sera from mice immunized three times
intraperitoneally with SHe-KLH or KLH in combination with incomplete Freund’s adjuvant, and pooled sera of mice infected with HRSV A2 (HRSV). HRSV-specific
ELISA of human (B) and mouse (D) sera. The ELISA plates in (B) and (D) were coated with the supernatant of HRSV A2 infected cells and tested with the sera used in
(A) and (C).
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(FccRIIb in mouse and FccRIIB in human) on the surface of innate
immune effector cells such as monocytes, macrophages, NKs, DCs,
neutrophils, eosinophils, and mast cells (Bruhns, 2012). Using
(FccRI, FccRIII)/ BALB/c mice, we demonstrated that the reduc-
tion of pulmonary HRSV replication mediated by SHe immune
serum strongly depends on FccRI and/or FccRIII. In addition, condi-
tional depletion of resident alveolar macrophages (rAM) signifi-
cantly but not completely abrogated the effect of SHe immune
serum on HRSV pulmonary titers. The residual antiviral effect of
SHe immune serum could be explained by the observation that rAM
depletion was not complete (Fig 6B). Alternatively, this may indi-
cate that other Fcc R expressing cells such as infiltrating monocytes,
NK cells, and neutrophils could also be involved, especially at later
time points during infection (Supplementary Fig S7).
Therefore, we propose a mechanism in which rAM cooperate
with SHe-specific IgG to target infected cells rather than free virions.
rAM might also indirectly contribute to SHe immune serum-
mediated inhibition of viral replication. Recently, it has become
clear that the crosstalk between macrophages and NK cells is
important for the host response to pathogens and tumors (Nedvetzki
et al, 2007; Lapaque et al, 2009; Klezovich-Benard et al, 2012).
Depletion of rAM by clodronate liposomes was shown to impair
early NK infiltration and activation in the lungs of HRSV-infected
mice (Pribul et al, 2008). In this way, macrophages might also
promote SHe-specific, antibody-dependent, NK-mediated ADCC of
HRSV-infected cells. However, our observation that depletion of NK
cells does not impact the activity of SHe immune serum argues
against a pivotal role for NK cells.
It is clear that in both experimental models, mice and cotton rats,
the impact of SHe protein vaccination on HRSV replication (6 to
70-fold reduction) does not seem to match up to the sterilizing
immunity that some of the F protein-based vaccine candidates elicit,
including the FI-HRSV vaccine used here in cotton rats. However,
one has to take into account that both BALB/c mice and cotton rats
are only semi-permissive for HRSV infection, and so high-titer inoc-
ula delivered directly to the lower respiratory tract are required for
productive infection in these animals. In humans, HRSV infection
starts in the upper respiratory tract and viral spread to the lower
respiratory tract probably involves multiple rounds of infections. In
such a situation, when the number of infected cells increases gradu-
ally over time, antibodies that reduce HRSV replication by eliminat-
ing HRSV-infected cells could have a greater impact. SHe-specific
antibodies were not detected in human reference sera with HRSV-
neutralizing activity. Whereas F protein-based vaccination strategies
aim at increasing the level of HRSV-neutralizing antibodies, which
are already significantly present in sera from adults, a SHe-based
vaccination strategy would induce antibodies against an additional
immune -protective antigen. Taken into account that SHe-based
vaccination does not provide sterile immunity, clinical implementa-
tion of an HRSV vaccine based solely on SHe antigen is unlikely.
Adding SHe antigen to vaccine candidates that are based on HRSV F
and G, in order to induce neutralizing antibodies, or to vaccines that
aim at inducing protective T cells, would be an interesting approach
to increase immune protection.
There is increasing evidence that non-neutralizing antibodies that
can mediate ADCC contribute significantly to protection against HIV
infections. The recent RV144 phase III trial for the first time resulted
in some level of protection (31% compared to placebo) (Rerks-Ngarm
et al, 2009). Surprisingly, this protection did not correlate with the
induction of neutralizing antibodies but with high levels of non-
neutralizing antibodies capable of mediating ADCC (Rerks-Ngarm
et al, 2009; Bonsignori et al, 2012; Haynes et al, 2012; Liao et al,
2013). Likewise, not the presence of neutralizing antibodies but the
presence of high levels of antibodies capable of ADCC in breast milk
correlates with protection against vertical transmission of HIV via
breastfeeding (Mabuka et al, 2012). Moreover, the protective activ-
ity of a broadly neutralizing HIV antibody in macaques relies largely
on its interaction with Fc receptors (Hessell et al, 2007). In addition,
ADCC exerted by cross-reactive HA-specific antibodies is associated
with cross-protective immunity against the 2009 pandemic H1N1 in
macaque monkeys that had been previously infected with seasonal
H1N1 (Jegaskanda et al, 2013). Moreover, in animal models, protec-
tion against influenza infections by antibodies directed against the
conserved ectodomain of the influenza M2 protein strongly depends
on Fcc receptors on macrophages (El Bakkouri et al, 2011). Next to
the non-neutralizing M2e antibodies, also the recently discovered
human ‘broadly neutralizing’ antibodies that bind to the conserved
stalk of influenza HA require on Fcc receptors for their protective
activity in vivo (Corti & Lanzavecchia, 2013; Dilillo et al, 2014).
These examples indicate that induction of antibodies able to elimi-
nate infected cells by Fc receptor-expressing host cells could be an
effective strategy for development of vaccines against intracellular
pathogens.
In infants, HRSV pathology is characterized by airway occlusion
caused by sloughed HRSV-infected cells (Welliver et al, 2008). This
feature of HRSV pathology in infants can be mimicked in HRSV-
infected mice in which alveolar macrophages were depleted by
clodronate liposomes (Reed et al, 2008; Welliver et al, 2008). This
indicates that macrophages might help to avert airway occlusion by
clearing HRSV-infected cells that are sloughed off as well as apopto-
tic leukocytes. Hence, it was suggested that vaccination strategies
that stimulate local macrophage function might be particularly effec-
tive in infants (Reed et al, 2008).
For a vaccine or antibody treatment based on a small antigen,
it is crucial that the antigen is highly conserved in time and among
strains. Recently, a small number of studies described SH coding
sequences or complete HRSV genome sequences of clinical
isolates. These studies included isolates collected between 1998
and 2011 in Europe, Brazil, and the USA and belonging to different
HRSV A genotypes (GA1, GA2, GA4, GA5, and GA7) (Kumaria
et al, 2011; Rebuffo-Scheer et al, 2011; Lima et al, 2012; Tan et al,
2013a,b). To evaluate the conservation of the ectodomain of HRSV
A subgroup SH, we aligned the SHe sequences from these studies
(Supplementary Fig S10 and S11). Of the 135 retrieved sequences,
5 isolates (3.7%) displayed one amino acid substitution compared
to the consensus sequence. None of the sequences displayed more
than one amino acid substitution. No deletions or insertions were
observed. In addition, SHe of the HRSV A laboratory strains RSV
A2 (M74568) and RSV long (AY911262), respectively, isolated in
1961 in Australia and in 1956 in the USA, and the RSS-2
(NC001803) line-19 (FJ614813) and HRSV A Tracy used in our
cotton rat model, are identical to the consensus amino acid
sequence. Importantly, the sequence of SHe from group A HRSV
and group B HRSV differs substantially (Chen et al, 2000). There-
fore, a SHe comprising HRSV vaccine candidate should contain
both the SHeA and the SHeB antigen.
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In conclusion, SHe-based immunity is not based on natural
immunity and entails an ADCC-type or ADCP-type of protective
mechanism and therefore can be considered complementary to F-,
G- and N-based subunit immunization strategies that are being
explored (Graham, 2011; Remot et al, 2012). Additional preclinical
development of this SHe-based vaccine might benefit from addi-
tional evaluation in an animal model that is more permissive for
HRSV or demonstration of its efficacy in natural hosts for HRSV-
related paramyxoviruses that also encode SH. In addition, we
propose that a viable path for further clinical evaluation of SHe
would be to include this antigen in other HRSV vaccine candidates




All mouse experiments described in this study were conducted
according to the national (Belgian Law 14/08/1986 and 22/12/2003,
Belgian Royal Decree 06/04/2010) and European (EU Directives
2010/63/EU, 86/609/EEG) animal regulations. All experiments on
mice were animal protocols approved by the ethics committee of
Ghent University (permit number LA1400091, approval ID 2007/
027, 2010/025, and 2013/025). All efforts were made to avoid or
ameliorate suffering of animals. The cotton rat experiment was
performed in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The experimental protocols were approved by
the BCM Investigational Animal Care and Use Committee.
Cells and viruses
Hep-2 cells (ATCC, CCL-23), Vero cells (ATCC, CCL-81), and A549
cells ATCC, CCL-185) were grown at 37°C in the presence of 5%
CO2 in DMEM supplemented with 10% heat-inactivated fetal calf
serum (FCS), 1% penicillin, 1% streptomycin, 2 mM L-glutamine,
non-essential amino acids (Invitrogen, Carlsbad, California), and
1 mM sodium pyruvate. HRSV A2 (VR-1540) and HRSV B1 (VR-1580)
were obtained from ATCC (ATCC, Rockville). The clinical HRSV B
isolates were obtained from Gasthuisberg University Medical
Hospital of Leuven, Belgium, and described in Tan et al (2013a,b)
(JX576729, JX576730, and JX576731, see Supplementary Fig S8). All
HRSVs were propagated on sub-confluent Hep-2 cells infected with
0.1–0.01 MOI. Three days after infection, the culture medium was
collected and cleared by centrifugation (1,000 × g) for 15 min. The
supernatant was adjusted to 10% PEG and incubated at 4°C with
agitation for 4 h. Subsequently, HRSV was isolated by centrifugation
(4,000 × g) for 30 min at 4°C. The HRSV pellet was resuspended in
HBSS containing 20% sucrose, aliquoted, and stored at 80°C. The
infectious units in the HRSV stocks were quantified in duplicate or
triplicate on Vero cells by plaque assay.
Mice
Specific pathogen-free female BALB/c mice at the age of 7–8 weeks
were purchased from Charles River, and (FccRI, FccRIII)/ mice
(BALB/c genetic background) were originally obtained from Dr.
Verbeek and bred in the specific pathogen-free (SPF) animal facility
of DMBR (Hazenbos et al, 1996). All mice were genotyped by a PCR
protocol using genomic DNA. The mice were housed in a SPF
temperature-controlled environment with 12-h light/dark cycles and
given water and food ad libitum. Mice were used at 9 weeks of age
after adaptation in the animal room for 1 week.
Production of SHe–KLH antigen
For chemical conjugation of SHe to keyhole limpet hemocyanin
(KLH), we used a SHe peptide variant (CGGGS-NKLSEYNVFHNKT-
FELPRARVNT) in which the cysteine at position 4 in the natural
SHe amino acid sequence was substituted by a serine to prevent
conjugation at this position. An N-terminal CGGGS linker was added
as a flexible spacer separating SHe from the carrier. KLH-peptide
conjugation and isolation was performed using the Imject Malei-
mide-Activated mcKLH Kit (Thermo Fisher Scientific, Rockford,
USA) according to the manufacturer’s instructions.
Production of HBc-SHeB antigen
A peptide corresponding to the SH ectodomain of HRSV B with an
N-terminal CGGGS linker and cysteine at position 10 replaced by a
serine (CGGGS-NKLSEHKTFSNKTLEQGQMYQINT) was chemically
conjugated to Hepatitis B core protein virus-like particles (HBc-
SHeB) by using the heterobifunctional crosslinker Sulfo-MBS
according to the manufacturer’s instructions (Pierce, Rockford,
USA). The production and purification of recombinant HBc particles
in which a single lysine was inserted in the immune dominant loop
between amino acids 76 and 77 to allow chemical conjugation is
described in De Filette et al (2005).
Mice immunization and infection
At the age of 9 weeks, the mice were immunized intraperitoneally
with 20 lg antigen dissolved in PBS to a volume of 100 ll PBS and
mixed with 100 ll incomplete Freund’s adjuvant or the Sigma Adju-
vant System (Sigma-Aldrich, St. Louis, USA). Immunizations were
performed three times at 3-week intervals, unless indicated other-
wise. Two weeks after each immunization, blood samples were
collected from the lateral tail vein. Blood was left to clot at 37°C for
30 min, and serum was collected by taking the supernatant from
two consecutive centrifugations. The serum titers of SHe-specific
IgG, IgG1, and IgG2a were determined by peptide ELISA. Three
weeks after the final immunization, the mice were sedated with
isoflurane and challenged intranasally with 1 × 106 PFU of HRSV or
a different dose as specified. Five days after infection, the mice were
killed by cervical dislocation. The lungs were collected and homoge-
nized with a Heidolph RZR 2020 homogenizer in 1.0 ml HBSS
containing 20% sucrose. The lung homogenates were cleared by
centrifugation (1,000 × g) for 15 min at 4°C and used to determine
the viral titer by plaque assay on Vero cells.
Immunization and infection of cotton rats
This experiment was performed at Baylor College by Dr. PA.
Piedra and Dr. B. Gilbert. Cotton rats (Sigmoden hispidis) of both
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genders were bred and housed in the Baylor College of Medicine
(Houston, TX, USA) vivarium in cages covered with barrier filters
and given food and water ad libitum. Cotton rats were immu-
nized intraperitoneally with PBS or with 100 lg KLH or SHe-KLH
dissolved in 100 ll PBS and mixed with 100 ll incomplete
Freund’s adjuvant. Immunizations were performed three times at
3-week intervals. At the time of the first immunization, one group
of cotton rats were infected intranasally with 2.04 × 105 PFU of
HRSV Tracy (HEp-2 grown) under light sedation with isoflurane,
and one group were immunized in the left tibialis anterior with
formalin-inactivated HRSV-Bernett grown in Vero cells (Piedra
et al, 1989). Blood was collected 3 weeks after each immuniza-
tion. Twenty-four days after the last immunization, all cotton rats
were challenged with 2.25 × 105 PFU of HRSV Tracy (100 ll)
under light sedation with isoflurane. Five days after challenge,
the cotton rats were euthanized with CO2. The left lung was tied
off and used for histopathology. The remaining right lobes from
the lung were removed, rinsed in sterile water to remove external
blood contamination, and weighed. The right lobes were transpleu-
rally lavaged using 3 ml of Iscove’s medium with 15% glycerin
mixed with 2% FBS-MEM (1:1, v:v) injected at multiple sites to
totally inflate the lobes. Lavage fluid was recovered by gently flat-
tening the inflated lobes and stored on ice until titered. For nasal
washes of the upper respiratory tract, the jaws were disarticu-
lated. The head was then removed, and 1 ml of Iscove’s media
with 15% glycerin mixed with 2% FBS-MEM (1:1, v:v) was
pushed through each nare (total of 2 ml). The effluent was
collected from the posterior opening of the pallet and stored on
ice until titered. The virus titer in the lung lavage fluids and
nasal washes was determined by plaque assay using HEp-2 cells.
Six days after infection with duplicate dilution series of the
prepared lung lavage fluids and nasal washes, the viral plaques
were stained with 0.1% crystal violet in 10% formalin solution
and counted. For histopathology, the left lung was perfused with
10% neutral buffered formalin (for 2 h). Tissues were stored in
10% neutral buffered formalin and sent to the Center for Compar-
ative Medicine, BCM, where the pathologist who assigned the
qualitative and quantitative histopathological scores was blinded
to the group assignments.
Adoptive serum transfer experiments
SHe-KLH, KLH, and PBS immune sera were obtained from mice
that had been immunized 3 times with 20 lg SHe-KLH or KLH in
combination with incomplete Freund’s adjuvant (Merck Milipore,
Billerica, USA),with PBS or from immunologically naive mice that
had been infected with 1 × 106 PFU of HRSV to obtain serum with
virus-neutralizing activity. Three weeks after the third immunization,
blood was obtained from the orbital sinus of mice anesthetized with
an intraperitoneal injection of avertin (2.5% in PBS). Blood was left
to clot at 37°C for 30 min, and serum was obtained by taking the
supernatant from two consecutive centrifugations. The serum was
heat-inactivated by incubation at 56°C for 30 min. In passive immu-
nization experiments, 35 ll of heat-inactivated serum was adminis-
tered intranasally under isoflurane sedation 24 h before and 24 h
after HRSV challenge. Five days after challenge with 106 PFU HRSV,
the mice were sacrificed and their lungs were excised to determine
viral load.
ELISA
ELISA was used to determine antibody titers in sera from individual
mice, or pooled sera. To determine SHe-specific IgG in mouse,
cotton rat, and human sera, microtiter plates (type II F96 MaxiSorp,
Nunc) were coated with 0.2 lg SHe peptide (NKLCEYNVFHNKT-
FELPRARVNT) in 100 ll of 50 mM sodium bicarbonate buffer, pH
9.7, and incubated overnight at 37°C. A peptide corresponding to
the influenza M2 ectodomain (SLLTEVETPIRNEWGCRCNDSSD)
was used as negative control. Alternatively, microtiter plates were
coated at 4°C with supernatant of cultured Vero cells that had been
infected with HRSV A2. After washing, the plates were blocked for
1 h with 200 ll of 1% BSA in PBS. After 1-h incubation, the plates
were washed again. Unless specified otherwise, a series of threefold
dilutions of different mouse, cotton rat, or human serum samples,
starting with a 1/100 dilution, were loaded on the coated plates.
The following human serum samples were obtained from the NIH
Biodefense and Emerging Infections Research Resources Respira-
tory: NR-40210, human reference antiserum to respiratory syncytial
virus; NR-4021: human antiserum to respiratory syncytial virus,
high control; NR-4022, human antiserum to respiratory syncytial
virus, medium control; NR-4023, human antiserum to respiratory
syncytial virus, low control; and NR-21973, human reference
immune globulin to respiratory syncytial virus (Yang et al, 2007).
The bound antibodies were detected with individual or a mixture of
peroxidase-labeled antibodies directed against mouse isotypes IgG1,
IgG2a, IgG2b, or IgG3 (individually diluted 1/6,000) (Southern
Biotechnology Associates, Inc., Birmingham, AL, USA), or against
human IgG1, IgG2, IgG3, and IgG4 (individually diluted 1/2,000)
(Southern Biotechnology Associates, Inc.), or against cotton rat IgG
(diluted 1/1,000) (Immunology Consultants Laboratory Inc., Port-
land, USA) in PBS + 1% BSA + 0.05% Tween 20. After washing, the
microtiter plates were incubated for 5 min with TMB substrate (tet-
ramethylbenzidine, Sigma-Aldrich). The reaction was stopped by
adding an equal volume 1 M H2SO4, and absorbance at 450 nm was
measured. Endpoint titers were defined as the highest dilution
producing an O.D. value twice that of background (pre-immune
serum).
Plaque assay
Monolayers of Vero cells were infected with 50 ll of serial three-
fold dilutions of the lung homogenates in a 96-well plate in serum-
free OptiMEM medium (Invitrogen) supplemented with penicillin
and streptomycin. After 3 h, the medium was removed and the
cells were washed twice with PBS. After adding 150 ll of growth
medium containing 2% FCS and 0.6% avicel RC-851 (FMC
Biopolymers), the cells were incubated for 4–5 days at 37°C. After
infection, the cells were washed twice with PBS and subsequently
fixed in 2% paraformaldehyde. After overnight fixation at 4°C, the
paraformaldehyde solution was removed and the cells were
washed twice with PBS. Subsequently, the cells were permeabi-
lized with PBS containing 0.2% Triton X-100 for 5 min and
blocked with PBS containing 1% BSA. The viral plaques were
stained with a polyclonal goat anti-HRSV serum (AB1128, Chemicon
International) (1/4,000). After washing three times with 1% BSA
in PBS, the cells were incubated with HRP-conjugated anti-goat
IgG antibodies (SC2020, Santa Cruz) for 30 min. Non-binding
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antibodies were removed by washing four times with PBS contain-
ing 1% BSA and 0.01% Triton X-100 and once with PBS. Finally,
the plaques were visualized by using TrueBlue peroxidase
substrate (KPL, Gaithersburg). The plaques of different dilutions
were counted, and for each dilution, the number of PFU per lung
(1 ml of lung homogenate) was calculated as the number of
plaques present in the dilution × the factor of dilution × 20
(20 = 1,000 ll total supernatant volume/50 ll of supernatant used
to infect the first well of the dilution series). The number of PFU/
lung was then calculated as the average number of PFU/lung
calculated for the different dilutions. As each supernatant of the
homogenized lungs was tested in duplicate, the final number of
PFU/lung was calculated as the average of these duplicates.
In vitro neutralization using mouse sera
Virus neutralization activity of mouse sera was tested by plaque
reduction assay. Mouse sera (not heat inactivated) were diluted in
serum-free medium and incubated with approximately 50 PFU
HRSV for 30 min at 37°C in a final volume of 50 ll. These samples
were then used to infect a confluent cell layer of Vero cells grown in
a 96-well plate. After 3 h incubation at 37°C, 150 ll of growth
medium containing 2% FCS and 0.6% avicel RC-851 (FMC Biopoly-
mers) was added. Three days after infection, plaque formation was
detected by immunostaining with goat anti-HRSV serum and HRP-
coupled anti-goat IgG. The stained plaques were visualized by using
TrueBlue peroxidase substrate (KPL, Gaithersburg, USA) and
counted visually. Alternatively, viral antigen was detected by adding
100 ll TMB substrate. After incubation for a few min, 50 ll of color-
ized TMB substrate of each sample was mixed with an equal
volume of 1 M H2SO4 in a 96-well plate and absorbance was
measured at 450 nm.
In vitro neutralization of cotton rat sera
Tests for serum neutralizing antibodies to HRSV Tracy were
performed with HEp-2 cells grown in 96-well microtiter plates.
Serial twofold dilutions in duplicates starting at 3 log2 were
performed to determine the neutralizing antibody (Ab) titer for each
sample. The neutralizing antibody titer was defined as the serum
dilution resulting in > 50% reduction in viral cytopathic effect
(CPE). CPE is determined visually after the wells are fixed with 10%
neutral buffered formalin and stained with crystal violet. Neutraliz-
ing antibody titers are categorical log numbers and not continuous
values. The lowest detectable Nt Ab titer is 2.5 log2. Samples with
non-detectable neutralizing antibody titers were assigned a value of
2 log2.
QPCR of HRSV B RNA in BALF of infected mice
The relative levels of HRSV B N cDNA were determined by qRT–
PCR using primers specific for the HRSV B N RNA (RSVB-N-Fw:
50-GGCTCCAGAATATAGGCATGATTC-30 and RSVB-N-Rev 50-TGGTT-
ATTACAAGAGCAGCTATACACAGT-30) and an HRSV B N-specific
FAM-conjugated nucleotide probe (50-TATCATCCCACAGTCTG-30).
The relative RNA level calculated as 1/2n (n is the number of PCR
cycles) with the calculated value for the mock-infected mice was
set as 1.
Detection of FccRI on the surface of resident alveolar
macrophages
BALF of 4 wild-type mice and 3 FccRI/ mice were prepared and,
respectively, pooled. After fixation with 1% PFA for 10 min at 4°C,
the BALF cells were washed and blocked with PBS containing 1%
BSA and 1 lg/ml anti-CD16/CD32 Fc-block for 1 h. Subsequently,
the cells were stained with PE/Texas Red-conjugated anti-CD11c in
combination with either Alexa647-conjugated anti-FccRI antibody or
a APC-conjugated mouse IgG1j isotype control antibody. For
unstained and single stain controls, a mixtures of wild-type and
FccRI/ BALF cells were used. Resident alveolar macrophages
were detected as highly autofluroscent (FITC channel), CD11c-
positive single cells. The samples were measured on a LSRII
flowcytometer and analyzed with Flowjo.
Depletion of alveolar macrophages and flowcytometric analysis
of BALF cells
Liposomes containing dichloromethylene diphosphonate (clodro-
nate) or PBS were prepared as described previously (Van Rooijen &
Sanders, 1994; Pribul et al, 2008). Fifty microliters of PBS or clodro-
nate-loaded liposomes were administered intranasally to isoflurane
sedated BALB/c mice 3 days before HRSV challenge. Depletion of
alveolar macrophages (AM) was ascertained by determining the cell
content of bronchoalveolar lavage (BAL) isolated 72 h after lipo-
some administration under anesthesia with an intraperitoneal injec-
tion of avertin (2.5% in PBS). A 23-gauge cannula was inserted into
the trachea, and cells were collected by washing the airway lumen
twice with 0.5 ml PBS containing 0.05 mM EDTA. Total numbers of
BAL cells were counted by using a Bu¨rker chamber (Marienfeld,
Lauda-Ko¨nigshofen, Germany). Trypan Blue was added to exclude
dead cells. BAL immune cell composition was determined on an
LSR-II flow cytometer (BD Biosciences) by analyzing cellular auto-
fluorescence and surface expression of CD3e, CD4, CD8a, CD11b,
CCR3, MHC-II, and CD11c, similar to the protocol described in
Schepens et al (2011). All antibodies were purchased from
Pharmingen (BD Biosciences) except for CCR3 (R&D Systems). For
challenge experiments, clodronate liposomes were administered
3 days before HRSV challenge. One day before and 1 day after HRSV
challenge, 35 ll of heat-inactivated SHe-KLH or KLH mouse immune
serum was administered intranasally to mice sedated with isoflurane.
Immunostaining HRSV-infected cells and cells to which HRSV
is attached
On day 1, 7 × 103 A549 cells were seeded on glass cover slips in two
different 24-well plates. On day 2, the cells of 1 plate were infected
with 1 MOI of HRSV A2. On day 3, the cells of the second plate were
washed once with cold PBS and then incubated with cold OptiMEM
medium containing either 5 MOI HRSV A2 or no virus for 2 h on ice.
Subsequently, all cells were washed twice with medium containing
10% FCS and twice with cold PBS. Next, the cells were fixed with
2% paraformaldehyde in PBS for 30 min on ice. After fixation, the
cells were washed twice with PBS and blocked with 1% BSA in PBS.
The cells were then stained with goat anti-HRSV serum (diluted
1/2,000 in 1% BSA in PBS) (AB1128, Millipore, Massachusetts, USA)
in combination with either an HRSV F-specific mouse monoclonal
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antibody (diluted 1/2,000 in 1% BSA in PBS) (MAB858-1, Millipore,
Massachusetts, USA) or serum (precleared overnight with detached
A549 cells and diluted 1/500 in 1% BSA) of KLH or SHe-KLH-immunized
mice. After washing three times with 1% BSA in PBS, the bound
goat and mouse IgG antibodies were detected with, respectively,
Alexa594-conjugated donkey anti-goat IgG and Alexa488-conjugated
donkey anti-mouse IgG antibodies (Invitrogen Molecular Probes,
Paisley, UK). The nucleus was stained with DAPI nuclear stain.
Images were recorded with a Leica TCS SP5 confocal microscope.
The infection and attachment samples were recorded with the same
settings. Images were processed with Volocity software (Perkin
Elmer, Massachusetts, USA). For the quantitative analysis of antibody
binding to HRSV virions attached to cells, seven images were used
for the samples stained with SHe-KLH serum and the F-specific
monoclonal antibody. One image was used for the control sample
stained with KLH serum.




Human respiratory syncytial virus (HRSV) is the major respiratory virus
in young infants. In adults and the elderly, HRSV closely follows influ-
enza virus as a cause of severe lower respiratory tract disease. Despite
decades of research, there is no licensed HRSV vaccine available.
Conventional HRSV vaccine candidates are mainly based on the
induction of neutralizing antibodies directed against the two major
HRSV surface proteins F and G. However, although high levels of
HRSV-neutralizing antibodies correlate with reduced incidence of
HRSV-associated hospitalization, humans with high levels of such
antibodies can still be infected. Moreover, boosting pre-existing HRSV-
neutralizing antibodies in humans by vaccination appears to be diffi-
cult. Therefore, we have explored an unconventional approach that
does not rely on the induction of virus-neutralizing antibodies or
mimics immune responses following natural infection, to develop an
HRSV vaccination strategy.
Results
We used the extracellular domain (SHe) of the small hydrophobic
domain of HRSV as a vaccine antigen. This domain is displayed on the
surface of infected cells and to a lesser extent on the surface of viri-
ons. We found that antibodies directed against this domain could be
generated by a vaccine comprising this domain. Immunization of mice
or cotton rats with this novel vaccine antigen resulted in significantly
reduced virus replication upon HRSV infection. We also propose a
likely mechanism of action of SHe-specific immunity. Using cellular
depletion experiments and mice with targeted disruption of FccRI and
FccRIII, we show that antibodies directed against SHe reduce HRSV
replication via IgG binding receptors and alveolar macrophages.
Finally, pre-existing humoral immunity against SHe is very low in the
human population, suggesting that HRSV has evolved in the absence
of SHe-based immunity.
Impact
Our work proposes a novel HRSV vaccination approach that targets
an HRSV antigen that is naturally not readily recognized by the host
adaptive immune system. This vaccine protects against HRSV by a
mechanism that is different from that of all other HRSV vaccine
approaches that have been explored to date. Hence, this new HRSV
vaccination approach might complement vaccination strategies based
on the induction of neutralizing antibodies.
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